CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• Localized high-risk soft tissue sarcomas (STSs) exhibit poor long-term survival.
• Identifying novel prognostic factors is crucial for improving patient outcomes.
• CXCR4, a chemokine receptor, plays a role in tumor progression, angiogenesis, and metastasis.

Purpose of the Study:

• To investigate the association between CXCR4 expression in tumor tissue and survival in STSs patients.
• To evaluate CXCR4 expression in relation to neoadjuvant therapy response and patient prognosis.

Main Methods:

• Retrospective analysis of CXCR4 expression using immunohistochemical analysis.
• Examination of serial specimens: initial biopsies, post-neoadjuvant treatment tumors, and tumors at relapse.
• Correlation of CXCR4 expression patterns with recurrence-free survival (RFS) and overall survival.

Main Results:

• Positive cytoplasmic CXCR4 expression in post-neoadjuvant tumors predicted poor RFS (p=0.003) and overall survival (p=0.019) in synovial sarcomas.
• Positive nuclear CXCR4 expression in initial biopsies was associated with poor RFS (p=0.022) in undifferentiated pleomorphic sarcomas.

Conclusions:

• CXCR4 expression in tumor tissue is a significant prognostic factor for STSs.
• CXCR4 may serve as a predictive biomarker for treatment response and patient survival in specific STS subtypes.